Biomea Fusion – LifeCareNews

LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283

Biomea Fusion Announces Dosing of First Patient with Type 2

COVALENT-111, now underway in the US, has completed Phase I and is currently enrolling type 2 diabetes patients in the Phase II randomized, placebo-controlled portion of the trialBMF-219, an orally available covalent menin inhibitor, is…

Biomea Fusion to Participate in Piper Sandler 34th Annual

REDWOOD CITY, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”)(Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and…